• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Histone deacetylase inhibition reveals a tumor-suppressive function of MYC-regulated miRNA in breast and lung carcinoma.组蛋白去乙酰化酶抑制揭示了MYC调控的miRNA在乳腺癌和肺癌中的肿瘤抑制功能。
Cell Death Differ. 2016 Aug;23(8):1312-21. doi: 10.1038/cdd.2016.9. Epub 2016 Feb 26.
2
MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors.MYC 转录调控 MCL1 和 eIF4E 基因以控制胃癌细胞对组蛋白去乙酰化酶抑制剂的敏感性。
Cell Cycle. 2012 Apr 15;11(8):1593-602. doi: 10.4161/cc.20008.
3
Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.联合组蛋白去乙酰化酶抑制与他莫昔芬通过逆转Bcl-2过表达,在他莫昔芬耐药的乳腺癌模型中诱导细胞凋亡。
Breast Cancer Res. 2015 Feb 25;17(1):26. doi: 10.1186/s13058-015-0533-z.
4
Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies.Myc在血液系统恶性肿瘤中响应HDAC抑制诱导miRNA介导的细胞凋亡。
Cancer Res. 2016 Feb 1;76(3):736-48. doi: 10.1158/0008-5472.CAN-15-1751. Epub 2015 Dec 16.
5
c-Myc overexpression sensitizes Bim-mediated Bax activation for apoptosis induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through regulating Bcl-2/Bcl-xL expression.c-Myc过表达通过调节Bcl-2/Bcl-xL的表达,使Bim介导的Bax激活对组蛋白去乙酰化酶抑制剂辛二酰苯胺异羟肟酸(SAHA)诱导的细胞凋亡敏感。
Int J Biochem Cell Biol. 2007;39(5):1016-25. doi: 10.1016/j.biocel.2007.01.024. Epub 2007 Feb 2.
6
Design, synthesis, and characterization of α, β-unsaturated carboxylic acid, and its urea based derivatives that explores novel epigenetic modulators in human non-small cell lung cancer A549 cell line.设计、合成及表征 α,β-不饱和羧酸及其脲基衍生物,以探索新型表观遗传调节剂在人非小细胞肺癌 A549 细胞系中的作用。
J Cell Physiol. 2018 Jul;233(7):5293-5309. doi: 10.1002/jcp.26333. Epub 2018 Jan 25.
7
Down-regulation of c-Met and Bcl2 by microRNA-206, activates apoptosis, and inhibits tumor cell proliferation, migration and colony formation.微小RNA-206对c-Met和Bcl2的下调作用可激活细胞凋亡,并抑制肿瘤细胞的增殖、迁移和集落形成。
Oncotarget. 2015 Sep 22;6(28):25533-74. doi: 10.18632/oncotarget.4575.
8
Molecular underpinnings of HDAC inhibition revealed.组蛋白去乙酰化酶抑制作用的分子基础得以揭示。
Cell Cycle. 2016 Aug 2;15(15):1943-4. doi: 10.1080/15384101.2016.1184513. Epub 2016 May 6.
9
Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.泛组蛋白去乙酰化酶抑制剂 ITF2357 对 c-Myc 过表达的人 B 细胞非霍奇金淋巴瘤的多效抗肿瘤作用。
Int J Cancer. 2014 Nov 1;135(9):2034-45. doi: 10.1002/ijc.28852. Epub 2014 Mar 26.
10
MiR-16 targets Bcl-2 in paclitaxel-resistant lung cancer cells and overexpression of miR-16 along with miR-17 causes unprecedented sensitivity by simultaneously modulating autophagy and apoptosis.微小RNA-16在耐紫杉醇肺癌细胞中靶向Bcl-2,微小RNA-16与微小RNA-17一起过表达通过同时调节自噬和凋亡导致前所未有的敏感性。
Cell Signal. 2015 Feb;27(2):189-203. doi: 10.1016/j.cellsig.2014.11.023. Epub 2014 Nov 27.

引用本文的文献

1
c-Myc knockdown restores tamoxifen sensitivity in triple-negative breast cancer by reactivating the expression of ERα: the central role of miR-152 and miR-148a.c-Myc基因敲低通过重新激活ERα的表达恢复三阴性乳腺癌对他莫昔芬的敏感性:miR-152和miR-148a的核心作用
Breast Cancer. 2025 May;32(3):529-542. doi: 10.1007/s12282-025-01683-w. Epub 2025 Mar 3.
2
Effects of Deacetylase Inhibition on the Activation of the Antioxidant Response and Aerobic Metabolism in Cellular Models of Fanconi Anemia.去乙酰化酶抑制对范科尼贫血细胞模型中抗氧化反应激活及有氧代谢的影响
Antioxidants (Basel). 2023 May 15;12(5):1100. doi: 10.3390/antiox12051100.
3
Characterization of the HDAC/PI3K inhibitor CUDC-907 as a novel senolytic.CUDC-907 作为一种新型的衰老细胞选择性抑制剂的特征。
Aging (Albany NY). 2023 Mar 28;15(7):2373-2394. doi: 10.18632/aging.204616.
4
Circular RNA circ_0000741/miR-379-5p/TRIM14 signaling axis promotes HDAC inhibitor (SAHA) tolerance in glioblastoma.环状 RNA circ_0000741/miR-379-5p/TRIM14 信号轴促进胶质母细胞瘤对组蛋白去乙酰化酶抑制剂(SAHA)的耐受。
Metab Brain Dis. 2023 Apr;38(4):1351-1364. doi: 10.1007/s11011-023-01184-9. Epub 2023 Mar 11.
5
STEAP1 regulation and its influence modulating the response of LNCaP prostate cancer cells to bicalutamide, enzalutamide and apalutamide.STEAP1 的调控及其对 LNCaP 前列腺癌细胞对比卡鲁胺、恩杂鲁胺和阿帕鲁胺反应的影响。
Mol Med Rep. 2023 Feb;27(2). doi: 10.3892/mmr.2023.12939. Epub 2023 Jan 20.
6
Integrated analysis of bulk and single-cell RNA-seq reveals the role of MYC signaling in lung adenocarcinoma.对批量和单细胞RNA测序的综合分析揭示了MYC信号通路在肺腺癌中的作用。
Front Genet. 2022 Oct 10;13:1021978. doi: 10.3389/fgene.2022.1021978. eCollection 2022.
7
An integrative systems biology approach to overcome venetoclax resistance in acute myeloid leukemia.一种综合系统生物学方法,克服急性髓系白血病中维奈托克的耐药性。
PLoS Comput Biol. 2022 Sep 13;18(9):e1010439. doi: 10.1371/journal.pcbi.1010439. eCollection 2022 Sep.
8
MTBP and MYC: A Dynamic Duo in Proliferation, Cancer, and Aging.MTBP与MYC:增殖、癌症及衰老过程中的活力组合
Biology (Basel). 2022 Jun 8;11(6):881. doi: 10.3390/biology11060881.
9
Anticancer Effect of Rh2, a Histone Deacetylase Inhibitor, in HepG2 Cells and HepG2 Cell-Derived Xenograft Tumors Occurs via the Inhibition of HDACs and Activation of the MAPK Signaling Pathway.组蛋白去乙酰化酶抑制剂 Rh2 对 HepG2 细胞及其衍生的异种移植瘤的抗癌作用是通过抑制组蛋白去乙酰化酶和激活 MAPK 信号通路实现的。
Asian Pac J Cancer Prev. 2021 Aug 1;22(8):2529-2539. doi: 10.31557/APJCP.2021.22.8.2529.
10
The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy.组蛋白去乙酰化酶及其抑制剂在癌症治疗中的作用
Front Cell Dev Biol. 2020 Sep 29;8:576946. doi: 10.3389/fcell.2020.576946. eCollection 2020.

本文引用的文献

1
MicroRNA-31 is a transcriptional target of histone deacetylase inhibitors and a regulator of cellular senescence.微小RNA-31是组蛋白去乙酰化酶抑制剂的转录靶点以及细胞衰老的调节因子。
J Biol Chem. 2015 Apr 17;290(16):10555-67. doi: 10.1074/jbc.M114.624361. Epub 2015 Mar 3.
2
Inactivation of p53 is insufficient to allow B cells and B-cell lymphomas to survive without Dicer.p53 的失活不足以使 B 细胞和 B 细胞淋巴瘤在没有 Dicer 的情况下存活。
Cancer Res. 2014 Jul 15;74(14):3923-34. doi: 10.1158/0008-5472.CAN-13-1866. Epub 2014 May 19.
3
HDAC 1/4-mediated silencing of microRNA-200b promotes chemoresistance in human lung adenocarcinoma cells.组蛋白去乙酰化酶1/4介导的微小RNA-200b沉默促进人肺腺癌细胞的化疗耐药性。
Oncotarget. 2014 May 30;5(10):3333-49. doi: 10.18632/oncotarget.1948.
4
Oncogenic protein MTBP interacts with MYC to promote tumorigenesis.致癌蛋白 MTBP 与 MYC 相互作用促进肿瘤发生。
Cancer Res. 2014 Jul 1;74(13):3591-602. doi: 10.1158/0008-5472.CAN-13-2149. Epub 2014 May 1.
5
New and emerging HDAC inhibitors for cancer treatment.新型和新兴的 HDAC 抑制剂在癌症治疗中的应用。
J Clin Invest. 2014 Jan;124(1):30-9. doi: 10.1172/JCI69738. Epub 2014 Jan 2.
6
miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma.miR-223 调节细胞生长并靶向蕈样肉芽肿/皮肤 T 细胞淋巴瘤中的原癌基因。
J Invest Dermatol. 2014 Apr;134(4):1101-1107. doi: 10.1038/jid.2013.461. Epub 2013 Nov 7.
7
MicroRNAs in cancer.微小 RNA 与癌症。
Annu Rev Pathol. 2014;9:287-314. doi: 10.1146/annurev-pathol-012513-104715. Epub 2013 Sep 25.
8
Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells.miR-125a、miR-125b 和 miR-205 在恩替诺特诱导乳腺癌细胞 erbB2/erbB3 下调和凋亡中的功能协同作用。
Cell Death Dis. 2013 Mar 21;4(3):e556. doi: 10.1038/cddis.2013.79.
9
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.组蛋白修饰治疗侵袭性 B 细胞淋巴瘤中 MYC 介导的 miR-29 的 HDAC3 和 EZH2 协同沉默。
Cancer Cell. 2012 Oct 16;22(4):506-523. doi: 10.1016/j.ccr.2012.09.003.
10
An integrated encyclopedia of DNA elements in the human genome.人类基因组中 DNA 元件的综合百科全书。
Nature. 2012 Sep 6;489(7414):57-74. doi: 10.1038/nature11247.

组蛋白去乙酰化酶抑制揭示了MYC调控的miRNA在乳腺癌和肺癌中的肿瘤抑制功能。

Histone deacetylase inhibition reveals a tumor-suppressive function of MYC-regulated miRNA in breast and lung carcinoma.

作者信息

Adams C M, Eischen C M

机构信息

Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.

出版信息

Cell Death Differ. 2016 Aug;23(8):1312-21. doi: 10.1038/cdd.2016.9. Epub 2016 Feb 26.

DOI:10.1038/cdd.2016.9
PMID:26915294
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4947678/
Abstract

Histone deacetylase (HDAC) inhibition leads to dynamic changes in the epigenetic landscape that is postulated to alter the expression of critical mediators of cellular proliferation and death. While current HDAC inhibitors have shown to be efficacious in the treatment of specific hematologic malignancies, their therapeutic utility in epithelial-based cancers warrants further evaluation. Moreover, the mechanisms of HDAC inhibition-induced cancer cell death are not completely understood. Therefore, elucidation of the underlying pathways engaged by HDAC inhibition may enable the development of more effective therapeutic strategies. Here, we report that HDAC inhibition in human breast and lung carcinoma cells activates an apoptotic mechanism mediated by microRNA (miRNA) and induced by the oncogene MYC. Specifically, following HDAC inhibition, MYC, which normally represses miR-15 and let-7 families, transcriptionally activated their expression and MYC was required for this miRNA upregulation. As a result, transcript levels of the tumor-suppressive miR-15 and let-7 families increased, which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL, respectively. MYC was also required for the downregulation of BCL-2 and BCL-XL following HDAC inhibition. Blocking the binding sites of the miR-15 and let-7 families in the 3'-untranslated regions of BCL-2 and BCL-XL protected against HDAC inhibition-induced apoptosis. These results provide important insight into the molecular underpinnings of HDAC inhibition-induced cell death in breast and lung cancer and reveal a tumor-suppressive role for MYC-regulated miRNA that is activated with HDAC inhibition.

摘要

组蛋白去乙酰化酶(HDAC)抑制作用会导致表观遗传格局发生动态变化,据推测这种变化会改变细胞增殖和死亡关键调节因子的表达。虽然目前的HDAC抑制剂已显示出对特定血液系统恶性肿瘤的治疗效果,但其在基于上皮细胞的癌症中的治疗效用仍有待进一步评估。此外,HDAC抑制诱导癌细胞死亡的机制尚未完全明确。因此,阐明HDAC抑制作用所涉及的潜在途径可能有助于开发更有效的治疗策略。在此,我们报告HDAC抑制人乳腺癌和肺癌细胞会激活一种由微小RNA(miRNA)介导且由癌基因MYC诱导的凋亡机制。具体而言,HDAC抑制后,通常抑制miR-15和let-7家族的MYC会转录激活它们的表达,且这种miRNA上调需要MYC。结果,肿瘤抑制性的miR-15和let-7家族的转录水平增加,它们分别靶向并降低了关键的促生存基因BCL-2和BCL-XL的表达。HDAC抑制后BCL-2和BCL-XL的下调也需要MYC。阻断BCL-2和BCL-XL的3'-非翻译区中miR-15和let-7家族的结合位点可防止HDAC抑制诱导的细胞凋亡。这些结果为HDAC抑制诱导乳腺癌和肺癌细胞死亡的分子基础提供了重要见解,并揭示了在HDAC抑制作用下被激活的MYC调节的miRNA的肿瘤抑制作用。